Alliance Pharma plc

AIM:APH Stock Report

Market Cap: UK£329.7m

Alliance Pharma Future Growth

Future criteria checks 4/6

Alliance Pharma is forecast to grow earnings and revenue by 65.7% and 5.2% per annum respectively. EPS is expected to grow by 78.7% per annum. Return on equity is forecast to be 10.7% in 3 years.

Key information

65.7%

Earnings growth rate

78.7%

EPS growth rate

Pharmaceuticals earnings growth18.2%
Revenue growth rate5.2%
Future return on equity10.7%
Analyst coverage

Good

Last updated12 Jan 2025

Recent future growth updates

Recent updates

Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues

Sep 10
Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues

Is Alliance Pharma (LON:APH) A Risky Investment?

Jun 21
Is Alliance Pharma (LON:APH) A Risky Investment?

Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet

Feb 23
Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet

Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)

Nov 21
Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)

We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt

May 26
We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt

Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

Mar 24
Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

Sep 30
We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

May 28
An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Mar 30
Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

Dec 24
Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

Nov 19
Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

Earnings and Revenue Growth Forecasts

AIM:APH - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202721426N/AN/A1
12/31/20262112533436
12/31/20252012028416
12/31/20241891627406
6/30/2024183-342930N/A
3/31/2024182-333031N/A
12/31/2023181-333131N/A
9/30/2023175-313030N/A
6/30/2023170-292929N/A
3/31/2023169-252525N/A
12/31/2022167-212021N/A
9/30/2022165-52627N/A
6/30/2022163123234N/A
3/31/2022163103336N/A
12/31/202116373439N/A
9/30/2021155133439N/A
6/30/2021147183439N/A
3/31/2021138133640N/A
12/31/202013083842N/A
9/30/2020131103337N/A
6/30/2020131112932N/A
3/31/2020133183034N/A
12/31/2019136253236N/A
9/30/2019133232832N/A
6/30/2019130212427N/A
3/31/2019124202125N/A
12/31/2018118181922N/A
9/30/2018112212224N/A
6/30/2018107242426N/A
3/31/201810427N/A27N/A
12/31/201710229N/A27N/A
9/30/201710125N/A27N/A
6/30/201710022N/A26N/A
3/31/20179920N/A22N/A
12/31/20169718N/A17N/A
9/30/20168518N/A13N/A
6/30/20167218N/A9N/A
3/31/20166015N/A9N/A
12/31/20154813N/A8N/A
9/30/20154711N/A9N/A
6/30/2015458N/A9N/A
3/31/2015448N/A10N/A
12/31/2014448N/A11N/A
9/30/2014448N/A11N/A
6/30/2014449N/A10N/A
3/31/2014459N/A10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: APH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: APH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: APH is expected to become profitable in the next 3 years.

Revenue vs Market: APH's revenue (5.2% per year) is forecast to grow faster than the UK market (3.5% per year).

High Growth Revenue: APH's revenue (5.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: APH's Return on Equity is forecast to be low in 3 years time (10.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 02:24
End of Day Share Price 2025/01/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alliance Pharma plc is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Julie SimmondsCanaccord Genuity
Mark BrewerCavendish